Mr Canavan wrote to Mike Malone-Lee: "As for HCV testing, I don't think anyone was under any illusions but that it was marginal in terms of cost benefit. But this is true of other NHS interventions. However the litigation factor, the introduction of testing elsewhere in Europe and the prospect of EC harmonisation of licensing requirements for blood products stacked up in favour of testing."